Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system
characterized by focal or diffuse inflammation, demyelination, axonal loss and …

Background Fatigue is a common and debilitating symptom in multiple sclerosis (MS). Over
the past decade, a growing body of research has focussed on the pathophysiological …

Introduction Multiple sclerosis (MS) is characterised by the accumulation of permanent
neurological disability secondary to irreversible tissue loss (neurodegeneration) in the brain …

Background: Change in ventricular volume has been suggested as surrogate measure of
central brain atrophy (CBA) applicable to the everyday management of multiple sclerosis …

Objective To evaluate the combined effect of lesion activity and pathologic processes
occurring in both chronically demyelinated lesions and normal-appearing white matter …

Background: In relapsing-remitting multiple sclerosis, no evidence of disease activity-3
(NEDA-3) is defined as no relapses, no disability progression and no MRI activity. NEDA-4 …

Multiple sclerosis (MS) is a chronic disease which usually begins in young adulthood and is
a lifelong condition. Individuals with MS experience physical and cognitive disability …

Objective In the pivotal DEFINE and CONFIRM trials for dimethyl fumarate (DMF), patterns of
brain volume changes were different, potentially due to low sample sizes and because MRIs …

Abstract Background and Purpose In multiple sclerosis (MS), brain atrophy measurements
have emerged as an important biomarker reflecting neurodegeneration and disability …

Objectives: To analyze the correlation between corpus callosum index (CCI), brain
volumetry, and disability in multiple sclerosis (MS) patients. The brain volumetry consists of …